ACD Awarded $1.4 Million NCI Grant
News Oct 08, 2014
Advanced Cell Diagnostics, Inc. (ACD) has been awarded a two-year, $1.4 million grant from National Cancer Institute (NCI) under its SBIR Phase II Program. ACD and its academic partner Cleveland Clinic will use the grant to develop and validate a diagnostic test based on ACD’s proprietary RNAscope® technology for discriminating various B-cell non-Hodgkin lymphomas (NHLs) from benign lymphoproliferative diseases.
“This award is a further validation of the clinical utility of RNAscope technology. We are very pleased that NCI has recognized the diagnostic potential of RNAscope technology and are grateful for its continued support”, commented by Dr Yuling Luo, President and CEO of ACD.
Detection of B-cell clonality by demonstrating the restricted expression of one of the two immunoglobulin light chains (kappa or lambda) provides valuable molecular information for the diagnosis of NHLs. Formalin-fixed paraffin-embedded (FFPE) tissue is often the only sample type available for diagnostic testing in many clinical settings, however there has been a long-standing technical challenge in detecting light chain mRNAs in these tissues.
“In Phase I, we developed a manual RNAscope-based assay for light chain mRNAs and demonstrated that it allowed determination of light chain restriction in virtually all types of NHL using FFPE with 99% concordance with the current gold standard assay flow cytometry using fresh tissue”, said Xiao-Jun Ma, Ph.D., ACD’s Chief Scientific Officer, and Principal Investigator.
“This is an important advance in our ability to accurately diagnose B-cell lymphomas because conventional IHC (immunohistochemistry) and CISH (chromogenic in situ hybridization) methods to establish clonality simply don’t work for the majority of NHLs for various reasons”, said James Cook, M.D/Ph.D., hematopathologist and co-investigator at Cleveland Clinic.
The Phase II grant will develop a fully automated assay and advanced image analysis algorithms for objective interpretation to facilitate clinical adoption.
Generating T Cells With a More Powerful Anti-cancer EffectNews
Studies of two T cell types that are equally activated by alpha-fetoprotein, a well-established antigen made by liver cancer, show that while one starts off with a bang, the other endures as the more powerful tumor fighter.READ MORE
Cancer Cells’ Energy Source Blocked by Natural CompoundNews
Researchers have not only untangled an unusual wiring system that cancer cells use for carbohydrate metabolism, but also identified a natural compound that appears to selectively shut down this system in laboratory studies.READ MORE
First Ever Online Event Focused on Cannabis ScienceNews
Analytical Cannabis is pleased to announce that the final line-up of speakers for the first ever cannabis science online event, The Science of Cannabis 2017 has been confirmed.READ MORE